Cabenuva 300 mg (Rilpivirine KIT) 300 MG

Cabenuva 300 mg is an injectable medication containing rilpivirine, used for HIV treatment. This kit provides a convenient, long-acting solution for managing the virus.

Strength

300 MG

Manufacturer / TM Owner

VIIV HEALTHCARE ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Cabenuva 300 mg is primarily used in the treatment of HIV-1 infection in adults. It is a combination therapy that includes rilpivirine, an antiretroviral medication. This treatment is designed for patients who are already on a stable antiretroviral regimen and are looking for a long-acting injectable option. Cabenuva is administered intramuscularly, providing a convenient alternative to daily oral medications.

Side Effects

Common effects of Cabenuva 300 mg may include injection site reactions, such as pain, redness, or swelling. Some individuals might experience headaches, fatigue, or gastrointestinal issues. These effects vary among users and typically subside as the body adjusts to the medication.

Precautions & Warnings

Cabenuva 300 mg should be handled with care, ensuring proper storage and administration by healthcare professionals. It is important to discuss any pre-existing medical conditions or allergies with your healthcare provider before starting this treatment. Regular monitoring and follow-up are recommended to ensure the medication's effectiveness and safety.

Avoid Interactions

Cabenuva 300 mg may interact with certain medications, including those that affect liver enzymes, such as CYP3A inhibitors or inducers. It is crucial to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions. Alcohol consumption should be discussed with your healthcare provider, as it may affect the medication's efficacy.

Frequently Asked Questions

Cabenuva 300 mg is used for the treatment of HIV-1 infection in adults who are already on a stable antiretroviral regimen.

Cabenuva 300 mg is administered intramuscularly by a healthcare professional.

Common side effects may include injection site reactions, headaches, fatigue, and gastrointestinal issues.

It is important to discuss all medications with your healthcare provider to avoid potential interactions.

Cabenuva 300 mg is typically administered once a month after initial doses.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.